International Isotopes INC

Radnostix Inc. announced the approval of its 2026 Incentive Plan and the election of five directors at its 2026 Annual Meeting of Shareholders.

Radnostix, Inc. has acquired the Lara System technology platform and Ellexa Explorer Software from Lucerno Dynamics, LLC for an initial purchase price of $900,000, comprising cash and stock, with potential for future milestone and earnout payments.

Radnostix Inc. has extended the maturity date of its Series C Convertible Redeemable Preferred Stock by one year to February 28, 2028, with all other terms remaining unchanged.

Radnostix, Inc. announced the mutual termination of its Asset Purchase Agreement for the DUF6 Plant and initiated a voluntary recall of certain Dibasic Sodium Phosphate Capsules.

International Isotopes Inc. has officially changed its corporate name to Radnostix, Inc., reflecting an expanded focus on healthcare-related radioisotopes and theranostics.

International Isotopes Inc. announced a new long-term employment agreement for its CEO, appointed a new director with nuclear pharmacy expertise, and updated its corporate bylaws to enhance governance.

Radnostix Inc. reported a significant decrease in revenue for Q2 2026, driven by product recalls and operational impacts, alongside an increased net loss, though key debt agreements were modified.

Radnostix Inc. reported a significant decrease in revenue for the first quarter of 2026, primarily due to voluntary product recalls and operational shutdowns, leading to a substantial net loss.

International Isotopes Inc. reported an increased net loss for Q3 2025, driven by supply chain disruptions and an FDA Official Action Indicated, despite strategic growth initiatives.

International Isotopes Inc. reported a reduced net loss and increased revenue for the second quarter and first half of 2025, driven by strong Nuclear Medicine Standards sales.

International Isotopes Inc. saw a 12% increase in revenue for Q1 2025, primarily driven by growth in its Nuclear Medicine Standards segment, while experiencing a net loss of $112,694.

International Isotopes Inc. saw a significant improvement in its third-quarter results, driven by increased sales in its Theranostics and Cobalt product segments, despite a global shortage impacting its Nuclear Medicine Standards business.

Radnostix Inc. filed an amendment to its 2025 Annual Report to provide required disclosures regarding corporate governance, executive compensation, and related party transactions.

Radnostix Inc. reported a 6% revenue decrease and a net loss in 2025, while advancing product development and terminating a major asset sale.

International Isotopes Inc. filed an amendment to its 2024 annual report to include previously omitted information regarding directors, executive compensation, security ownership, related transactions, and principal accountant fees.

International Isotopes Inc. achieved its highest annual revenue and a net income for fiscal year 2024, marking a significant turnaround from the previous year's net loss.

International Isotopes Inc. achieved its highest annual revenue in company history in 2023, driven by growth in its theranostics and nuclear medicine segments.

Radnostix Inc. reports a $500,000 convertible promissory note with Kershner, Grosso & Co., convertible into common stock at $0.07 per share.

Director Christopher G. Grosso acquired 581,536 shares of Radnostix Inc. common stock as a dividend payment on preferred holdings.

International Isotopes Inc. Director Robert Atcher received a grant of 250,000 restricted stock units, increasing his total beneficial ownership to 1,000,000 shares.

International Isotopes Inc. Director Steve Laflin acquired 500,000 stock options with an exercise price of $0.06 per share under a Rule 10b5-1 plan.

International Isotopes Inc. Director and 10% owner Christopher G. Grosso acquired 500,000 stock options with an exercise price of $0.06.

International Isotopes Inc. CEO Shahe Bagerdjian was granted 37.5 million restricted stock units, vesting upon achievement of specific share price and cash metrics.

Radnostix Inc. has issued its proxy statement for the 2026 Annual Meeting of Shareholders, detailing proposals for director elections, auditor ratification, and an incentive plan.

International Isotopes Inc. is changing its corporate name to Radnostix, Inc. to reflect its strategic shift towards radiopharma and theranostics in healthcare.

International Isotopes Inc. has filed definitive additional proxy materials (DEFA14A) with the U.S. Securities and Exchange Commission.

International Isotopes Inc. has scheduled its 2025 Annual Meeting of Shareholders to vote on the election of directors, ratification of its accounting firm, executive compensation, and a proposed reverse stock split ranging from 1-for-50 to 1-for-275 to boost share price and facilitate major exchange listing.

International Isotopes Inc. has filed a definitive proxy statement with the SEC.

International Isotopes Inc. will hold its 2024 Annual Meeting of Shareholders on July 10, 2024, to elect directors and ratify the appointment of its independent registered public accounting firm.

Kennerman Associates and Christopher Grosso report significant beneficial ownership of Radnostix Inc. common stock, totaling over 42% and 12% respectively, as of December 31, 2025.

Kennerman Associates, Inc. and its principal, Christopher Grosso, have filed an updated Schedule 13G, revealing their combined beneficial ownership of 42.4% and 12.1% respectively, in International Isotopes Inc. as of December 31, 2024.